BARCELONA, Spain--(BUSINESS WIRE)--The journal Annals of the Rheumatic Diseases (the highest impact journal in rheumatology worldwide with an impact factor of 9.270) has just published in its online edition the results of the clinical trial MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa). The main conclusion of the study is that the combination of chondroitin sulfate plus glucosamine has comparable efficacy to the anti-inflammatory drug celecoxib after six months of treatment in severe osteoarthritis. Specifically, it was seen that the combination of these two drugs caused a clinically relevant reduction in pain, functional disability, stiffness, swelling and joint effusion, improving all the parameters studied:
“This study confirms the efficacy of the combination of pharmaceutical grade-chondroitin sulfate and glucosamine in the long term and suggests that, considering its excellent safety profile, it may be a good alternative for patients with cardiovascular or gastrointestinal problems, for whom chronic treatment with NSAIDs cannot be recommended”
- Reduction in pain: 50.1%.
- Reduction in functional disability: 45.5%.
- Reduction in stiffness: 46.9%.
- Reduction in swelling: 53%.
- Reduction in joint effusion: 56%.
“This study confirms the efficacy of the combination of pharmaceutical grade-chondroitin sulfate and glucosamine in the long term and suggests that, considering its excellent safety profile, it may be a good alternative for patients with cardiovascular or gastrointestinal problems, for whom chronic treatment with NSAIDs cannot be recommended” explained Prof. Marc C. Hochberg, rheumatologist of the University of Maryland School of Medicine (Baltimore, USA) and member of the study’s scientific committee.
Study design
MOVES is a multicenter, randomized, parallel-group, double-blind, controlled clinical trial, sponsored by Bioibérica, in which 606 patients with primary knee osteoarthritis and moderate to severe pain were recruited from 42 centers in Spain, Germany, France and Poland. A multidisciplinary team of investigators including rheumatologists, orthopaedists and primary care physicians participated in the study.
Designed according to good clinical practice guidelines, current legislation and regulations for drug research in osteoarthritis, the study also included a Scientific Committee formed by internationally renowned specialists for its supervision.
The primary objective was to show that the combination of chondroitin sulfate plus glucosamine is comparable in efficacy to celecoxib in the treatment of moderate to severe pain in patients with knee osteoarthritis. Patients were given pharmaceutical grade chondroitin sulfate (1200 mg/day) and glucosamine hydrochloride (1500 mg/ day) or 200 mg of celecoxib (anti-inflammatory drug) daily for six months.
The results confirmed those obtained in the GAIT study by Clegg’s group in 2006 and published in the New England Journal of Medicine, where the combination was superior to placebo in patients with moderate to severe pain. “In fact, MOVES was developed as an extension from GAIT, to confirm these results. Since GAIT compared the combination versus celecoxib and placebo, the MOVES trial was designed as a non-inferiority study comparing only the combination versus celecoxib”, stated Prof. Allen Sawitzke, rheumatologist of the University of Utah School of Medicine (Salt Lake City, USA) who participated in the design of the two studies.
These results provide final confirmation of the efficacy and safety of the combination of chondroitin sulfate plus glucosamine for the treatment of knee osteoarthritis.
Contacts
Alba Soler Conangla
PR- Corporate Communications Director
Bioiberica S.A.
Tel. +34 93 490 49 08/ + 34 682 04 07 76
asoler@bioiberica.com
Help employers find you! Check out all the jobs and post your resume.
